Novartis CEO Says COVID-19 Makes Valuing Takeover Targets Tougher
For instance, the company, like others, abandoned a trial of its older malaria medicine hydroxychloroquine after it failed to help patients in scientific …
Source: Novartis CEO Says COVID-19 Makes Valuing Takeover Targets Tougher